On 15 December, Cognition Therapeutics, a biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina, announced the expansion of its Phase II SHINE clinical trial from US to include sites in Europe. The SHINE study is a double-blind and placebo-controlled Phase II clinical trial designed to enroll up to 144 people with mild-to-moderate Alzheimer’s disease (AD). Participants will be randomised to receive either placebo or one of two doses of CT1812, taken orally daily for six months. Brain Research Center in Amsterdam (Netherlands) is the first European site to enroll participants in the Phase II SHINE study. The trial will also include sites in Spain and Czech Republic.